FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 175 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... May 21, 2019 New Combination of Old Drugs Improves Survival in Patients with Prostate... September 19, 2021 New on NCI’s Websites for September 2020 September 2, 2020 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... 11 Sun Safety Myths Debunked New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan
